|1.||Luszczki, Jarogniew J: 5 articles (01/2014 - 02/2006)|
|2.||Antkiewicz-Michaluk, Lucyna: 5 articles (12/2013 - 06/2004)|
|3.||Czuczwar, Stanislaw J: 3 articles (05/2010 - 02/2006)|
|4.||Haratym-Maj, Agnieszka: 2 articles (01/2014 - 12/2013)|
|5.||Andres-Mach, Marta: 2 articles (01/2014 - 12/2013)|
|6.||Raszewski, Grzegorz: 2 articles (12/2013 - 05/2010)|
|7.||Kotake, Yaichiro: 2 articles (07/2006 - 05/2002)|
|8.||Okuda, Katsuhiro: 2 articles (07/2006 - 05/2002)|
|9.||Ohta, Shigeru: 2 articles (07/2006 - 05/2002)|
|10.||Abe, K: 2 articles (11/2001 - 09/2001)|
01/01/2014 - "The aim of this study was to characterize the anticonvulsant effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline (1-MeTHIQ) in combination with clobazam (CLB) in the mouse maximal electroshock-induced seizure (MES) model. "
01/01/2014 - "Additive interactions between 1-methyl-1,2,3,4-tetrahydroisoquinoline and clobazam in the mouse maximal electroshock-induced tonic seizure model--an isobolographic analysis for parallel dose-response relationship curves."
12/01/2013 - "Effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline on the protective action of various antiepileptic drugs in the maximal electroshock-induced seizure model: a type II isobolographic analysis."
01/14/2009 - "Isobolographic analysis of interactions between 1-methyl-1,2,3,4-tetrahydroisoquinoline and four conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model."
02/01/2006 - "1-Methyl-1,2,3,4-tetrahydroisoquinoline enhances the anticonvulsant action of carbamazepine and valproate in the mouse maximal electroshock seizure model."
|2.||Parkinsonian Disorders (Parkinsonism)
07/01/2006 - "Parkinsonism-preventing activity of 1-methyl-1,2,3,4-tetrahydroisoquinoline derivatives in C57BL mouse in vivo."
02/01/2006 - "1-Methyl-1,2,3,4-tetrahydroisoquinoline (1-MeTHIQ - an endogenous parkinsonism-preventing substance) administered intraperitoneally at a dose of 20 mg/kg considerably elevated the threshold for electroconvulsions in mice from 6.4 to 8.4 mA (P < 0.05). "
01/15/1999 - "Biosynthesis of a parkinsonism-preventing substance, 1-methyl-1,2,3,4-tetrahydroisoquinoline, is inhibited by parkinsonism-inducing compounds in rat brain mitochondrial fraction."
12/01/1991 - "1-Methyl-1,2,3,4-tetrahydroisoquinoline, decreasing in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse, prevents parkinsonism-like behavior abnormalities."
06/01/2004 - "The aim of this paper was to investigate whether rotenone, a pesticide causing experimental parkinsonism, causes direct damage to dopaminergic structure when injected intracerebrally and whether this action may be prevented by peripheral administration of 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ), an endogenous compound with anti-dopaminergic activity. "
|3.||Parkinson Disease (Parkinson's Disease)
09/01/2001 - "We carried out behavioral, pathological, and biochemical studies in order to determine whether the stereo-structure of 1-methyl-1,2,3,4-tetrahydroisoquinoline (1-MeTIQ) affects the onset of Parkinson's disease-like symptoms, which are induced by 1,2,3,4-tetrahydroisoquinoline (TIQ) in mice. "
|4.||Substance-Related Disorders (Drug Abuse)
|1.||Anticonvulsants (Antiepileptic Drugs)
|4.||Prostaglandins B (PGB)